By Counterforce Health Team in Therakos CELLEX (photopheresis system) —

How to Get Therakos CELLEX Photopheresis Covered by Cigna in Washington: Complete Prior Authorization and Appeals Guide

Answer Box: Getting Therakos CELLEX Covered by Cigna in Washington

Therakos CELLEX photopheresis requires prior authorization from Cigna's medical team (not Express Scripts) for FDA-approved conditions like CTCL or steroid-refractory GVHD. Submit via CoverMyMeds with specialist notes documenting failed standard therapies. If denied, Washington residents can appeal through Cigna's internal process, then request IRO external review through the state Insurance Commissioner within 30 days. External reviews overturn ~25-35% of denials when proper medical evidence is provided.

Table of Contents

  1. Coverage at a Glance
  2. Step-by-Step: Fastest Path to Approval
  3. Medical vs. Pharmacy Benefit: Why This Matters
  4. ICD-10 and CPT Coding Requirements
  5. Common Denial Reasons & How to Fix Them
  6. Appeals Process in Washington State
  7. Clinician Corner: Medical Necessity Documentation
  8. Costs and Patient Support Options
  9. FAQ

Coverage at a Glance

Requirement What It Means Where to Find It
Prior Authorization Required via medical team CoverMyMeds portal
Approved Conditions CTCL (stages I-IV), steroid-refractory GVHD FDA labeling
Step Therapy Failed standard treatments required Clinical documentation
CPT Code 36522 (photopheresis procedure) Standard medical billing
Site of Care Outpatient facility with CELLEX system Network verification needed
Appeal Deadline 180 days internal, 30 days for IRO Washington OIC guidelines

Step-by-Step: Fastest Path to Approval

1. Verify Coverage and Network Status

Who does it: Patient or clinic staff
What's needed: Cigna member ID, provider NPI
How: Call Cigna at 1-800-882-4462 or check online portal
Timeline: Same day

2. Gather Required Documentation

Who does it: Treating physician and clinic
What's needed:

  • Confirmed diagnosis (pathology report for CTCL, transplant records for GVHD)
  • Documentation of failed standard therapies with dates and outcomes
  • Specialist consultation notes (hematology/oncology, dermatology, or transplant medicine)
  • Recent labs (CBC, CMP within 30 days)

3. Submit Prior Authorization

Who does it: Prescribing physician or clinic staff
How: CoverMyMeds ePA portal (preferred) or fax to 1-855-840-1678
Timeline: Standard 5 business days, expedited 72 hours for urgent cases
Required elements:

  • Patient demographics and Cigna ID
  • CPT code 36522
  • Appropriate ICD-10 codes (C84.A for CTCL, D89.81 for GVHD)
  • Clinical justification with specialist oversight

4. Track Authorization Status

Who does it: Clinic staff
How: CoverMyMeds dashboard or call 1-800-882-4462
Timeline: Check within 3-5 business days

5. If Denied: File Internal Appeal

Who does it: Patient, physician, or authorized representative
How: Submit written appeal to Cigna Appeals Unit, PO Box 188011, Chattanooga, TN 37422
Timeline: Within 180 days of denial notice
Required: Original denial letter, additional clinical evidence, medical necessity justification

6. If Internal Appeal Denied: Request IRO External Review

Who does it: Patient or physician
How: File with Washington Insurance Commissioner
Timeline: Within 30 days of internal appeal denial
Cost: Free to appellant

7. Begin Treatment Upon Approval

Who does it: Treatment facility
What's needed: Valid prior authorization number
Timeline: Treatment can begin immediately after approval

Medical vs. Pharmacy Benefit: Why This Matters

Therakos CELLEX photopheresis is covered under Cigna's medical benefit, not the pharmacy benefit managed by Express Scripts or Accredo. This distinction is crucial for several reasons:

Medical Benefit Coverage:

  • Prior authorization handled by Cigna's medical management team
  • Billed using CPT code 36522 for the procedure
  • Requires facility-based administration
  • Subject to medical deductibles and coinsurance

What This Means for Patients:

  • Don't contact Express Scripts or Accredo for authorization
  • Submit requests through medical prior authorization channels
  • Treatment must occur at approved outpatient facilities
  • Coverage follows medical benefit rules, not specialty pharmacy protocols
Note: Unlike many specialty medications that were removed from Cigna's prior authorization requirements in 2024-2025, extracorporeal photopheresis procedures remain subject to precertification due to their complexity and cost considerations.

ICD-10 and CPT Coding Requirements

Proper coding is essential for approval and billing. Here's what clinicians need to know:

Primary Diagnosis Codes

For Cutaneous T-Cell Lymphoma (CTCL):

  • C84.A - Cutaneous T-cell lymphoma, unspecified
  • C84.A0 - Unspecified site
  • C84.A9 - Extranodal and solid organ sites
  • Use specific site codes when location is documented

For Graft-Versus-Host Disease:

  • D89.81 - Graft-versus-host disease
  • D89.811 - Acute GVHD
  • D89.812 - Chronic GVHD
  • D89.813 - Acute on chronic GVHD

Procedure Codes

Primary CPT Code:

  • 36522 - Photopheresis, extracorporeal

Supporting Codes:

  • 36523 - Photopheresis, subsequent days (if applicable)
  • Q2079 - UV ACON treatment (HCPCS code)

Documentation Requirements

Each claim must include:

  • Confirmed pathology supporting the diagnosis
  • Stage/severity documentation (TNMB staging for CTCL)
  • Prior treatment failures with specific medications and timeframes
  • Clinical rationale for photopheresis
  • Specialist oversight confirmation

Common Denial Reasons & How to Fix Them

Denial Reason How to Overturn Required Documentation
Insufficient medical necessity Provide detailed clinical rationale with guidelines NCCN guidelines, specialist notes, disease progression data
Lack of step therapy compliance Document failed standard treatments Medication history, response/failure notes, intolerance documentation
Non-covered indication Clarify FDA-approved use FDA labeling, peer-reviewed studies, clinical guidelines
Frequency exceeds policy Justify treatment schedule Clinical response data, specialist recommendations
Missing specialist oversight Provide appropriate specialist involvement Hematology/oncology or dermatology consultation notes
From Our Advocates: We've seen many photopheresis denials overturned when providers include specific response measurements (like mSWAT scores for CTCL) and cite relevant clinical guidelines. The key is showing both medical necessity and appropriate specialist management. This composite guidance reflects common successful appeal strategies.

Appeals Process in Washington State

Washington provides robust consumer protections for insurance denials, including a strong external review process.

Internal Appeals with Cigna

First Level Appeal:

  • Deadline: 180 calendar days from denial notice
  • How to Submit: Written appeal to Cigna Appeals Unit
  • Address: PO Box 188011, Chattanooga, TN 37422
  • Timeline: Cigna has 60 days to respond
  • Required Documents:
    • Original denial letter/EOB
    • Additional clinical evidence
    • Provider statement of medical necessity

What to Include:

  • Complete medical records showing disease progression
  • Documentation of failed alternative treatments
  • Peer-reviewed literature supporting photopheresis efficacy
  • Specialist recommendations and oversight confirmation

External Review Through Washington IRO

If Cigna upholds the denial, Washington residents can request an Independent Review Organization (IRO) external review:

Eligibility: Automatic for fully insured plans in Washington
Deadline: 30 days from internal appeal denial
How to File: Through Washington Insurance Commissioner or directly with Cigna
Cost: Free to appellant
Timeline: Standard review within 30 days, expedited within 72 hours for urgent cases

IRO Process:

  1. Independent medical specialists review the case de novo
  2. IRO considers medical evidence, clinical guidelines, and plan terms
  3. Decision is binding on Cigna
  4. If overturned, Cigna must provide coverage

Success Rates: Washington IRO reviews overturn approximately 25-35% of denials when proper medical evidence is provided. Photopheresis appeals may have higher success rates due to established FDA approval and clinical guidelines.

When to Contact Washington Insurance Commissioner

The Washington Office of the Insurance Commissioner can help at any stage:

  • Consumer Advocacy Line: 1-800-562-6900
  • Services: Appeal guidance, template letters, complaint filing
  • Online Resources: Appeal forms and step-by-step guides

Clinician Corner: Medical Necessity Documentation

Essential Elements for Prior Authorization

Patient Assessment:

  • Confirmed histopathologic diagnosis
  • Disease staging (TNMB for CTCL, organ involvement for GVHD)
  • Functional status and quality of life impact
  • Previous treatment history with specific outcomes

Treatment Rationale:

  • Evidence-based justification for photopheresis
  • References to NCCN guidelines or other recognized standards
  • Expected treatment outcomes and monitoring plan
  • Facility capabilities and staff qualifications

Prior Therapy Documentation: For CTCL:

  • Topical corticosteroids with response/failure
  • PUVA or narrowband UV-B phototherapy results
  • Systemic therapies attempted (retinoids, interferons, chemotherapy)
  • Radiation therapy if applicable

For GVHD:

  • High-dose corticosteroids (≥1 mg/kg/day prednisone equivalent)
  • Secondary immunosuppressive agents (tacrolimus, cyclosporine, mycophenolate)
  • Novel agents (ruxolitinib, belumosudil) if tried
  • Documentation of steroid-refractory status

Sample Medical Necessity Statement

"This 65-year-old patient with biopsy-confirmed mycosis fungoides (C84.A9) presents with extensive skin involvement (>20% BSA) refractory to standard therapies. Prior treatments include high-potency topical corticosteroids (4 months, minimal response), PUVA therapy (6 months, disease progression), and systemic bexarotene (3 months, discontinued due to hyperlipidemia). Current disease staging T3N0M0B0 with significant pruritus and quality of life impairment. Extracorporeal photopheresis is FDA-approved for CTCL and recommended by NCCN guidelines for refractory disease. Treatment plan includes twice-monthly sessions with dermatology oversight and response monitoring via mSWAT scoring."

Costs and Patient Support Options

Insurance Coverage

  • Most commercial Cigna plans cover photopheresis for approved indications
  • Medicare Advantage plans typically provide coverage
  • Self-funded employer plans may vary (verify specific plan documents)

Patient Assistance

  • Therakos Patient Support: Contact manufacturer at therakos.com for coverage assistance
  • Treatment Centers: Many facilities have financial counselors to help with insurance navigation
  • State Programs: Washington Apple Health (Medicaid) may cover for eligible patients

Out-of-Pocket Considerations

  • Medical deductibles apply before coverage begins
  • Coinsurance typically 10-20% after deductible
  • Annual out-of-pocket maximums provide cost protection

FAQ

How long does Cigna prior authorization take for photopheresis?
Standard requests receive decisions within 5 business days via CoverMyMeds. Expedited requests for urgent cases can be processed within 72 hours by calling 1-800-882-4462.

What if photopheresis is denied as experimental?
Photopheresis has FDA approval for CTCL since 1993 and is included in NCCN guidelines. Appeal denials by citing FDA labeling and established clinical evidence. Washington's IRO external review is particularly effective for overturning "experimental" denials.

Can I get expedited appeals in Washington?
Yes, both Cigna internal appeals and Washington IRO external reviews offer expedited processes when health could be seriously jeopardized. Expedited IRO decisions typically come within 72 hours.

Does step therapy apply if I've tried treatments outside Washington?
Yes, prior therapy documentation from other states counts toward step therapy requirements. Ensure complete medical records are included with your prior authorization request.

What happens if my employer plan is self-funded?
Self-funded ERISA plans may not be subject to Washington state external review laws. However, many large employers voluntarily provide IRO access. Contact the U.S. Department of Labor for ERISA plan appeals if needed.

How successful are photopheresis appeals?
While specific statistics aren't publicly available, appeals with complete clinical documentation and specialist support have good success rates, especially when citing FDA approval and clinical guidelines. Washington's IRO process overturns 25-35% of denials overall.

About Counterforce Health

Counterforce Health helps patients, clinicians, and specialty pharmacies turn insurance denials into successful appeals. The platform analyzes denial letters and plan policies to create targeted, evidence-backed rebuttals that align with each payer's specific requirements. For complex treatments like photopheresis, Counterforce Health pulls the right clinical citations and weaves them into appeals that meet procedural requirements while tracking deadlines and required documentation.

Disclaimer: This guide provides general information about insurance coverage and appeals processes. It is not medical advice or a guarantee of coverage. Insurance policies vary, and coverage decisions depend on individual medical circumstances. Always consult with your healthcare provider and insurance plan for specific coverage questions. For assistance with appeals in Washington, contact the Office of the Insurance Commissioner at 1-800-562-6900 or visit insurance.wa.gov.

Sources & Further Reading

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.